ENHANCING PATIENT-CENTERED CARE THROUGH PREDICTIVE MODELING OF PATIENT-REPORTED OUTCOMES IN HOSPITAL PHARMACY SETTING
6ER-012
EVALUATION OF THE EFFECT OF CLOSED SYSTEM TRANSFER DEVICE SYRINGE ADAPTOR CONNECTION IN THE ISOLATOR ON CYTOTOXIC RESIDUE CONTAMINATION DURING INTRAVENOUS ADMINISTRATION
6ER-011
AN ASSESSMENT OF PHARMACISTS’ CONFIDENCE AND BEHAVIORS IN DISPENSING OPIOID MEDICATIONS
6ER-010
INVESTIGATING NEED AND APPROPRIATENESS FOR PHARMACIST-LED VACCINATION SERVICES WITHIN A HEALTHCARE SYSTEM
6ER-009
PRESCRIBING PATTERNS AND EFFECTIVENESS OF RANIBIZUMAB AND AFLIBERCEPT IN PATIENTS WITH CENTRAL RETINAL VEIN OCCLUSION: A RETROSPECTIVE COHORT STUDY IN TAIWAN
6ER-008
QUALITY, GAPS AND OPPORTUNITIES IN SMARTPHONE APPLICATIONS FOR PULMONARY HYPERTENSION: AN EVALUATION FROM HOSPITAL PHARMACISTS AND PATIENTS PERSPECTIVE
6ER-006
LABOUR PRODUCTIVITY GROWTH IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES UNDERGOING BIOLOGICAL OR JANUS KINASE INHIBITORS TREATMENT
6ER-005
DRUG WASTAGE: A HIDDEN COST OF CANCER CARE
6ER-004
VISION RELATED QUALITY OF LIFE IN PATIENTS WITH DIABETIC MACULAR OEDEMA AND AGE-RELATED MACULAR DEGENERATION TREATED WITH ANTIVASCULAR GROWTH FACTOR THERAPY OR DEXAMETHASONE
6ER-003
ASSESSMENT OF OVERALL SURVIVAL AND SAFETY IN NEWLY APPROVED ONCOHEMATOLOGIC DRUGS
6ER-002
POSITIVE PREDICTIVE VALUES OF ANAPHYLAXIS DIAGNOSIS IN CLAIMS DATA: A MULTI-INSTITUTIONAL STUDY IN TAIWAN
6ER-001
HEALTHCARE RESOURCE UTILIZATION AND COSTS OF INTRAVITREAL RANIBIZUMAB OR AFLIBERCEPT VS. DEXAMETHASONE FOR DIABETIC MACULAR EDEMA IN TAIWAN
6ER-034
USE OF CLOSED SYSTEM TRANSFER DEVICES WITH INVESTIGATIONAL DRUG PRODUCTS
6ER-033
PEMBROLIZUMAB AND ATEZOLIZUMAB AS POSSIBLE EQUIVALENT FIRST-LINE THERAPEUTIC ALTERNATIVES IN PDL1-EXPRESSING TRIPLE-NEGATIVE BREAST CANCER
6ER-032
HOW CAN DUTCH UNIVERSITY HOSPITALS CONTRIBUTE TO AFFORDABLE MEDICINES AND COST CONTAINMENT OF TOTAL HOSPITAL DRUG EXPENDITURE: A DELPHI STUDY
